REVELATIONS. L’annonce a été officialisée ce jour. Biond Biologics Ltd (Israël) et Sanofi signent un accord géant qui porte sur le traitement du cancer. Biond Biologics, qui développe une plateforme permettant la distribution intracellulaire de produits biologiques, notamment pour le champ de l’immuno-oncologie recevra $125 Millions de dollars en first cash. Sanofi est une entreprise transnationale française dont les activités incluent la pharmacie et les vaccins. Dans le secteur de la santé, Sanofi occupe le troisième rang mondial selon le chiffre d’affaires, mais seulement le onzième pour la capitalisation boursière;
LE PLUS. Sanofi to invest more than $1 billion developing Israeli cancer treatment The acquisition of Biond’s BND-22 cancer therapy may be the most lucrative deal ever for an Israeli product in the preclinical stages. (JPost)
Granting David Ben Moshe temporary residence is unneeded litmus test
Social media purge of Trump, supporters shows big tech’s responsibilities
Could it happen in Israel? – comment
Biden should strive to unite the US, help Israel protect itself – opinion
By YORAM DORI
To truly heal as a nation, we must have a deep national reckoning
By SHARON BROUS
Lab tests suggest Israeli-made face mask eliminates over 99% of coronavirus
Earth is spinning faster: Time flies in 50-year record
Pfizer: We don’t know if COVID-19 vaccine defends without second shot
Coronavirus lockdown to begin Thursday at midnight and last two weeks
‘Hitler was right on one thing,’ US congresswoman says at pro-Trump rally
LE PLUS. Israel’s Biond Biologics Ltd said on Tuesday it had forged an exclusive global licence agreement, potentially worth more than $1 billion, with French drugmaker Sanofi for the development and commercialization of its BND-22 cancer drug. Biond, a privately-held biopharmaceutical company, developing novel immunotherapies for cancer, said that it will receive a $125 million upfront payment in cash under the deal.
It will also be entitled to receive more than $1 billion in development, regulatory, and sales milestones, as well as tiered double-digit royalty payments, the company said. BND-22, Biond said, has been shown in preclinical studies to have a broad anti-tumor effect and that it had already submitted a new drug application to the U.S. Food and Drug Administration.
A Phase 1 study to evaluate the safety, tolerability, and preliminary anti-tumor activity of BND-22 in advanced cancer patients is planned to start by mid-2021. Biond will lead the first-in-human study of BND-22, evaluating its safety and tolerability as a single agent and in combination with approved cancer therapeutics, as well as exploring potential associations between BND-22 anti-tumor activity and select tumor and blood-based biomarkers.
Reporting by Steven Scheer; editing by Barbara Lewis
Our Standards: The Thomson Reuters Trust Principles.